Joshua Yeary, DO
Family Medicine · Ewing, VANPI 1720427834
Payments from drug & device makers
Across 288 payments — averaging $13.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$768
- AstraZeneca$307
- Amarin Pharma, Inc.$237
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$205
- Axsome Therapeutics, Inc.$145
- plus $1K from 18 others
What the payments were for
- Speaking & faculty fees$722%
- Food & beverage$3,73998%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 111 | $1,087 |
| Novo Nordisk | 67 | $768 |
| AstraZeneca | 18 | $307 |
| Amarin Pharma, Inc. | 13 | $237 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $205 |
| Axsome Therapeutics, Inc. | 7 | $145 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $138 |
| Pfizer | 9 | $135 |
| GSK | 8 | $120 |
| Abbott | 6 | $118 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $112 |
| Boehringer Ingelheim | 4 | $79 |
| Sanofi-aventis U.S. LLC | 1 | $72 |
| Bayer | 3 | $52 |
| Lilly USA, LLC | 3 | $50 |
| Biohaven Pharmaceuticals, Inc. | 2 | $38 |
| Astellas Pharma US Inc | 1 | $29 |
| Mylan Specialty L.p. | 2 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Shield Therapeutics Inc | 1 | $18 |
| Merck | 1 | $15 |
| Amgen | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Eisai Inc. | 1 | $12 |
How this compares
$3,811 in reported general payments places this provider in the 85th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 255 | $321,554 |
| FarxigaDapagliflozin Propanediol | 352 | $304,319 |
| EliquisApixaban | 339 | $251,579 |
| Tresiba Flextouch U-200Insulin Degludec | 127 | $182,507 |
| VascepaIcosapent Ethyl | 323 | $163,484 |
| MounjaroTirzepatide | 141 | $155,368 |
| LinzessLinaclotide | 157 | $103,963 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 105 | $101,247 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 105 | $69,978 |
| OtezlaApremilast | 14 | $69,690 |
| UbrelvyUbrogepant | 52 | $69,665 |
| JardianceEmpagliflozin | 71 | $68,327 |
| JanuviaSitagliptin Phosphate | 69 | $54,709 |
| RybelsusSemaglutide | 48 | $54,626 |
| VraylarCariprazine Hcl | 26 | $43,575 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $307 | $446,315560 claims |
| Novo NordiskOzempic, Rybelsus | $768 | $376,180303 claims |
| AbbVieLinzess, Ubrelvy, Vraylar, Creon, Qulipta | $1,087 | $291,372288 claims |
| PfizerEliquis | $135 | $251,579339 claims |
| Lilly USA, LLCMounjaro, Trulicity | $50 | $185,972163 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $79 | $107,567124 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $120 | $82,917136 claims |
| AmgenOtezla | $13 | $69,69014 claims |
| MerckJanuvia | $15 | $54,70969 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $205 | $39,69217 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $29 | $29,13644 claims |
| Axsome Therapeutics, Inc.Auvelity | $145 | $25,85028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Ewing
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
- Linda SchneiderHampton$2.1M
- Jennifer BrownMidlothian$1.3M
- Brian McCormickHampton$793K
- Jerome DanielNorth Chesterfield$779K
- Samir AbdelshaheedChesapeake$642K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.